Skip to main content
SpringerLink
Log in

Preoperative Evaluation of Sensitized Patients

  • Chapter
  • First Online:
Kidney Transplantation in Sensitized Patients

  • 336 Accesses

Abstract

Since donor-specific antibodies (DSA) can induce antibody-mediated rejection in renal allograft, it is important to characterize HLA antibodies of the patient. Various tests are performed to detect HLA antibodies, but each test has its own limitations. Complement-dependent cytotoxicity (CDC) can detect complement-fixing antibodies, but it can be affected by drugs and non-HLA antibodies. Flow cytometry crossmatch (FCXM) detects HLA antibodies with greater sensitivity than CDC, but it cannot distinguish cytotoxic and noncytotoxic antibodies, and can be affected by nonspecific binding of non-HLA antibodies. Single antigen bead (SAB) assay has the greatest sensitivity to detect HLA antibodies. However, such low-titer HLA antibodies detected by SAB assay might not be clinically significant, and since HLA antigens are artificially attached to microbeads, false positive, false negative, or prozone effect can happen. Other kinds of solid phase assays, such as C1q SAB assay and C3d assay, are used to detect HLA antibodies, which can activate complement cascade. These HLA antibody assays should be interpreted in a comprehensive way.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, et al. Definitions of histocompatibility typing terms. Blood. 2011;118(23):e180–3. https://doi.org/10.1182/blood-2011-05-353490.

    Article  CAS  PubMed  Google Scholar 

  2. Eurotransplant manual, version 4.5. Chapter 10 histocompatibility testing. Netherlands: Eurotransplant Foundation; 2018.

    Google Scholar 

  3. Organ Procurement and Transplantation Network, Policy 4: Histocompatibility; 2019. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_04.

  4. Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, et al. Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report. Am J Transplant. 2018;18(7):1604–14. https://doi.org/10.1111/ajt.14752.

    Article  PubMed  Google Scholar 

  5. Kumar V. Current status on the evaluation and management of the highly sensitized kidney transplant recipient. Curr Opin Nephrol Hypertens. 2015;24(6):570–5. https://doi.org/10.1097/mnh.0000000000000172.

    Article  PubMed  Google Scholar 

  6. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FH, et al. Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant. 2015;15(4):923–30. https://doi.org/10.1111/ajt.13167.

    Article  CAS  PubMed  Google Scholar 

  7. Kathryn JT. Basic histocompatibility testing methods. In: Chandraker A, Sayegh MH, Singh AK, editors. Core concepts in renal transplantation. New York, NY: Springer Science & Business Media; 2012. p. 21–42.

    Google Scholar 

  8. Dunckley H. HLA typing by SSO and SSP methods. Methods Mol Biol. 2012;882:9–25. https://doi.org/10.1007/978-1-61779-842-9_2.

    Article  CAS  PubMed  Google Scholar 

  9. Rajalingam R, Zhang Q, Cecka JM, Reed EF. Major histocompatibility complex. In: Li XC, Jevnikar AM, editors. Transplant immunology: Wiley-Blackwell; 2015. p. 85–102.

    Google Scholar 

  10. Duke JL, Lind C, Mackiewicz K, Ferriola D, Papazoglou A, Gasiewski A, et al. Determining performance characteristics of an NGS-based HLA typing method for clinical applications. HLA. 2016;87(3):141–52. https://doi.org/10.1111/tan.12736.

    Article  CAS  PubMed  Google Scholar 

  11. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 2008;86(6):820–5. https://doi.org/10.1097/TP.0b013e3181856f98.

    Article  CAS  PubMed  Google Scholar 

  12. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735–9. https://doi.org/10.1056/nejm196904032801401.

    Article  CAS  PubMed  Google Scholar 

  13. Hopkins KA. The basic lymphocyte microcytotoxicity tests: standard and AHG enhancement. In: Hahn AB, Land GA, Strothman RM, editors. ASHI laboratory manual. 4th ed. Mount Laurel, NJ: American Society for Histocompatibility and Immunogenetics; 2000.

    Google Scholar 

  14. Fuller TC, Phelan D, Gebel HM, Rodey GE. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation. 1982;34(1):24–9.

    Article  CAS  PubMed  Google Scholar 

  15. Amos DB, Bashir H, Boyle W, MacQueen M, Tiilikainen A. A simple micro cytotoxicity test. Transplantation. 1969;7(3):220–3.

    Article  CAS  PubMed  Google Scholar 

  16. Tellis VA, Matas AJ, Senitzer D, Louis P, Glicklich D, Soberman R, et al. Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation. 1989;47(1):127–9.

    Article  CAS  PubMed  Google Scholar 

  17. Barger B, Shroyer TW, Hudson SL, Deierhoi MH, Barber WH, Curtis JJ, et al. Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera. Race, transplant history, and HLA-DR1 phenotype. Transplantation. 1989;47(2):240–5.

    Article  CAS  PubMed  Google Scholar 

  18. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77(4):542–8.

    Article  CAS  PubMed  Google Scholar 

  19. Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol. 2001;12(12):2807–14.

    CAS  PubMed  Google Scholar 

  20. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation. 2000;69(7):1370–4.

    Article  CAS  PubMed  Google Scholar 

  21. Hamrick CW, Lebeck LK. Flow cytometric T and B cell crossmatching. In: Hahn AB, Land GA, Strothman RM, editors. ASHI laboratory manual. 4th ed. Mount Laurel, NJ: American Society for Histocompatibility and Immunogenetics; 2000.

    Google Scholar 

  22. Hetrick SJ, Schillinger KP, Zachary AA, Jackson AM. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol. 2011;72(4):330–6. https://doi.org/10.1016/j.humimm.2011.01.005.

    Article  CAS  PubMed  Google Scholar 

  23. Park H, Lim YM, Han BY, Hyun J, Song EY, Park MH. Frequent false-positive reactions in pronase-treated T-cell flow cytometric cross-match tests. Transplant Proc. 2012;44(1):87–90. https://doi.org/10.1016/j.transproceed.2011.12.048.

    Article  CAS  PubMed  Google Scholar 

  24. Hart JD, Lutz CT, Jennings CD, May JR, Nelson K, Jacobs S, et al. Falsely incompatible B-cell flow cytometry crossmatch after pronase treatment: a case report. Transplant Proc. 2015;47(3):831–3. https://doi.org/10.1016/j.transproceed.2014.12.022.

    Article  CAS  PubMed  Google Scholar 

  25. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19–47. https://doi.org/10.1097/TP.0b013e31827a19cc.

    Article  CAS  PubMed  Google Scholar 

  26. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7(2):408–15. https://doi.org/10.1111/j.1600-6143.2006.01644.x.

    Article  CAS  PubMed  Google Scholar 

  27. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 2007;357(13):1293–300. https://doi.org/10.1056/NEJMoa067160.

    Article  CAS  PubMed  Google Scholar 

  28. Gatault P, Jollet I, Paintaud G, Magdelaine C, Bridoux F, Lebranchu Y, et al. Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch. Hum Immunol. 2013;74(12):1616–8. https://doi.org/10.1016/j.humimm.2013.08.278.

    Article  CAS  PubMed  Google Scholar 

  29. Gloor JM, Moore SB, Schneider BA, Degoey SR, Stegall MD. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation. 2007;84(2):258-64. https://doi.org/10.1097/01.tp.0000269615.91036.52.

    Article  CAS  PubMed  Google Scholar 

  30. Lachmann N, Todorova K, Schulze H, Schonemann C. Luminex and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion. Transfus Med Hemother. 2013;40(3):182–9. https://doi.org/10.1159/000351459.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol. 2009;70(7):496–501. https://doi.org/10.1016/j.humimm.2009.04.001.

    Article  CAS  PubMed  Google Scholar 

  32. Schwaiger E, Wahrmann M, Bond G, Eskandary F, Bohmig GA. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation. 2014;97(12):1279–85. https://doi.org/10.1097/01.TP.0000441091.47464.c6.

    Article  CAS  PubMed  Google Scholar 

  33. Tait BD. Detection of HLA antibodies in organ transplant recipients - triumphs and challenges of the solid phase bead assay. Front Immunol. 2016;7:570. https://doi.org/10.3389/fimmu.2016.00570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Weinstock C, Schnaidt M. The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet. 2013;40(3):171–7. https://doi.org/10.1111/j.1744-313X.2012.01147.x.

    Article  CAS  PubMed  Google Scholar 

  35. Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol. 2015;26(7):1489–502. https://doi.org/10.1681/asn.2014080837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. American journal of transplantation 2013;13(7):1859–70. https://doi.org/10.1111/ajt.12287.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Montgomery RA, Leffell MS, Zachary AA. Transplantation of the sensitized patient: histocompatibility testing. In: Zachary AA, Leffell MS, editors. Transplantation Immunology. 2nd ed. New York: Humana Press; 2013. p. 117–25.

    Chapter  Google Scholar 

  38. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10(1):26–9. https://doi.org/10.1111/j.1600-6143.2009.02927.x.

    Article  CAS  PubMed  Google Scholar 

  39. Keith DS, Vranic GM. Approach to the highly sensitized kidney transplant candidate. Clin J Am Soc Nephrol. 2016;11(4):684–93. https://doi.org/10.2215/cjn.05930615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Bray RA, Nolen JD, Larsen C, Pearson T, Newell KA, Kokko K, et al. Transplanting the highly sensitized patient: the Emory algorithm. Am J Transplant. 2006;6(10):2307–15. https://doi.org/10.1111/j.1600-6143.2006.01521.x.

    Article  CAS  PubMed  Google Scholar 

  41. Friedlander R, Putheti P, Diaz E, Menon A, Ponce B, Muthukumar T, et al. On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-to-lot variations in MFI. Transplantation. 2013;96(4):e24–6. https://doi.org/10.1097/TP.0b013e31829c2481.

    Article  PubMed  Google Scholar 

  42. Israeli M, Pollack MS, Shaut CA, Halpin A, DiPaola NR, Youngs D, et al. Concordance and discordance in anti-HLA antibody testing. Transpl Immunol. 2015;32(1):1–8. https://doi.org/10.1016/j.trim.2014.10.003.

    Article  CAS  PubMed  Google Scholar 

  43. Pereira S, Perkins S, Lee JH, Shumway W, LeFor W, Lopez-Cepero M, et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol. 2011;72(6):492–8. https://doi.org/10.1016/j.humimm.2011.02.012.

    Article  CAS  PubMed  Google Scholar 

  44. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol. 2009;70(10):844–53. https://doi.org/10.1016/j.humimm.2009.06.020.

    Article  CAS  PubMed  Google Scholar 

  45. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D. HLA antibody specification using single-antigen beads--a technical solution for the prozone effect. Transplantation. 2011;92(5):510–5. https://doi.org/10.1097/TP.0b013e31822872dd.

    Article  CAS  PubMed  Google Scholar 

  46. Kamburova EG, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, et al. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. Am J Transplant. 2018;18(9):2274–84. https://doi.org/10.1111/ajt.14709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215–26. https://doi.org/10.1056/NEJMoa1302506.

    Article  CAS  PubMed  Google Scholar 

  48. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16(1):12–7. https://doi.org/10.1111/j.1399-3046.2011.01599.x.

    Article  CAS  PubMed  Google Scholar 

  49. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91(3):342–7. https://doi.org/10.1097/TP.0b013e318203fd26.

    Article  CAS  PubMed  Google Scholar 

  50. Schaub S, Honger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014;98(4):387–93. https://doi.org/10.1097/tp.0000000000000203.

    Article  CAS  PubMed  Google Scholar 

  51. Tyan DB. Application, technical issues, and interpretation of C1q for graft outcome. Curr Opin Organ Transplant. 2017;22(5):505–10. https://doi.org/10.1097/mot.0000000000000454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Duquesnoy RJ, Marrari M, Jelenik L, Zeevi A, Claas FH, Mulder A. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol. 2013;74(10):1271–9. https://doi.org/10.1016/j.humimm.2013.05.016.

    Article  CAS  PubMed  Google Scholar 

  53. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation. 2015;99(6):1151–5. https://doi.org/10.1097/tp.0000000000000699.

    Article  CAS  PubMed  Google Scholar 

  54. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol. 2006;67(11):847–62. https://doi.org/10.1016/j.humimm.2006.08.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation. 2004;78(2):190–3.

    Article  PubMed  Google Scholar 

  56. Heidt S, Witvliet MD, Haasnoot GW, Claas FH. The 25th anniversary of the Eurotransplant acceptable mismatch program for highly sensitized patients. Transpl Immunol. 2015;33(2):51–7. https://doi.org/10.1016/j.trim.2015.08.006.

    Article  PubMed  Google Scholar 

  57. Duquesnoy RJ. Should epitope-based HLA compatibility be used in the kidney allocation system? Hum Immunol. 2017;78(1):24–9. https://doi.org/10.1016/j.humimm.2016.10.008.

    Article  CAS  PubMed  Google Scholar 

  58. Cross AR, Lion J, Loiseau P, Charron D, Taupin JL, Glotz D, et al. Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs. Human immunology. 2016;77(11):1092–100. https://doi.org/10.1016/j.humimm.2016.04.003.

    Article  CAS  PubMed  Google Scholar 

  59. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation. 2012;94(2):172–7. https://doi.org/10.1097/TP.0b013e3182543950.

    Article  CAS  Google Scholar 

  60. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95(9):1113–9. https://doi.org/10.1097/TP.0b013e3182888db6.

    Article  CAS  Google Scholar 

  61. DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney international. 2012;82(5):598–604. https://doi.org/10.1038/ki.2012.190.

    Article  CAS  PubMed  Google Scholar 

  62. Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. Journal of the American Society of Nephrology: JASN. 2005;16(9):2804–12. https://doi.org/10.1681/asn.2004121130.

    Article  CAS  PubMed  Google Scholar 

  63. Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28(6):1912–23. https://doi.org/10.1681/asn.2016070797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea

    Soo-Kyung Kim

  2. Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

    Hyosang Kim

Authors
  1. Soo-Kyung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyosang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soo-Kyung Kim .

Editor information

Editors and Affiliations

  1. Department of General Surgery, Asan Medical Center, Seoul, Korea (Republic of)

    Duck Jong Han

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kim, SK., Kim, H. (2020). Preoperative Evaluation of Sensitized Patients. In: Han, D. (eds) Kidney Transplantation in Sensitized Patients. Springer, Singapore. https://doi.org/10.1007/978-981-10-7046-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7046-4_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7045-7

  • Online ISBN: 978-981-10-7046-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation